We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
How Much Did Skyrizi and Rinvoq Drive AbbVie's Q3 Performance?
Read MoreHide Full Article
Key Takeaways
AbbVie's Skyrizi and Rinvoq generated over 40% of total Q3 revenues, replacing Humira's lost sales.
Skyrizi sales jumped 46% to $4.71B and Rinvoq rose 34% to $2.18B, fueled by IBD demand.
AbbVie lifted Skyrizi guidance to $17.3B and expects combined drug sales to exceed $25B this year.
AbbVie’s (ABBV - Free Report) key top-line drivers are its newer immunology medicines, Rinvoq and Skyrizi. Sales of both these drugs have effectively replaced the company’s flagship drug, Humira, which began facing generic erosion in the United States starting in 2023. In the recently reported third-quarter 2025 results, Rinvoq and Skyrizi together generated more than 40% of AbbVie’s total revenues, underscoring their critical role in sustaining the company’s growth trajectory.
Skyrizi increased 46% year over year to $4.71 billion, Rinvoq added $2.18 billion, up 34%. These upticks were fueled by strong volume growth and continued market share gains across all approved indications, especially in the popular inflammatory bowel disease (IBD) space, which includes two conditions — ulcerative colitis (UC) and Crohn’s disease (CD). During its Q3 conference call, AbbVie noted that the two drugs together now command roughly half of the in-play market share in CD and nearly one-third in UC within the United States — reflecting strong physician adoption and continued demand for the therapies.
Based on the encouraging uptake for these two therapies, AbbVie has reported robust mid-single-digit revenue growth in the first nine months of this year, despite it being just under three years following the U.S. Humira LOE. The company recently raised its Skyrizi sales guidance by $200 million to $17.3 billion, driven by continued share gains in psoriasis and IBD. It expects combined Skyrizi and Rinvoq sales to surpass $25 billion this year.
Strong immunology market growth, market share gains and momentum from new indications, such as the recent launch of Skyrizi in UC, along with the potential for five new indications for Rinvoq over the next few years, are expected to drive these drugs’ future growth. While AbbVie expects to file a regulatory submission for Rinvoq for the alopecia areata indication before year-end, it also intends to submit a regulatory filing for the drug in vitiligo in early 2026. The company is on track to report data on late-stage studies evaluating Rinvoq in hidradenitis suppurativa and systemic lupus erythematosus indications next year. AbbVie believes that the next wave of potential approvals in Rinvoq could add roughly $2 billion to peak-year sales for the product.
ABBV’s Competition in the Immunology Space
The targeted market is highly competitive. A key player in this field is Johnson & Johnson (JNJ - Free Report) , which markets two blockbuster drugs, Stelara and Tremfya. Both of these J&J medications are approved for multiple immunology indications, including UC and CD. Since Stelara lost U.S. patent exclusivity earlier this year, J&J has shifted its focus to Tremfya to maintain its market position.
Another pharma giant expanding its presence in immunology is Eli Lilly (LLY - Free Report) , following the FDA approval of Omvoh for the UC indication in late 2023. Omvoh marked Lilly’s first immunology drug approved for a type of IBD in the United States, playing a key role in expanding its portfolio in this therapeutic area. The Lilly drug received FDA approval for the CD indication in January.
ABBV’s Price Performance, Valuation and Estimates
Shares of AbbVie have outperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a premium to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 16.19 times forward earnings, a tad higher than its industry’s average of 15.84. The stock is also trading above its five-year mean of 13.36.
Image Source: Zacks Investment Research
Bottom-line estimate movements for 2025 and 2026 have declined over the past 30 days.
Image: Shutterstock
How Much Did Skyrizi and Rinvoq Drive AbbVie's Q3 Performance?
Key Takeaways
AbbVie’s (ABBV - Free Report) key top-line drivers are its newer immunology medicines, Rinvoq and Skyrizi. Sales of both these drugs have effectively replaced the company’s flagship drug, Humira, which began facing generic erosion in the United States starting in 2023. In the recently reported third-quarter 2025 results, Rinvoq and Skyrizi together generated more than 40% of AbbVie’s total revenues, underscoring their critical role in sustaining the company’s growth trajectory.
Skyrizi increased 46% year over year to $4.71 billion, Rinvoq added $2.18 billion, up 34%. These upticks were fueled by strong volume growth and continued market share gains across all approved indications, especially in the popular inflammatory bowel disease (IBD) space, which includes two conditions — ulcerative colitis (UC) and Crohn’s disease (CD). During its Q3 conference call, AbbVie noted that the two drugs together now command roughly half of the in-play market share in CD and nearly one-third in UC within the United States — reflecting strong physician adoption and continued demand for the therapies.
Based on the encouraging uptake for these two therapies, AbbVie has reported robust mid-single-digit revenue growth in the first nine months of this year, despite it being just under three years following the U.S. Humira LOE. The company recently raised its Skyrizi sales guidance by $200 million to $17.3 billion, driven by continued share gains in psoriasis and IBD. It expects combined Skyrizi and Rinvoq sales to surpass $25 billion this year.
Strong immunology market growth, market share gains and momentum from new indications, such as the recent launch of Skyrizi in UC, along with the potential for five new indications for Rinvoq over the next few years, are expected to drive these drugs’ future growth. While AbbVie expects to file a regulatory submission for Rinvoq for the alopecia areata indication before year-end, it also intends to submit a regulatory filing for the drug in vitiligo in early 2026. The company is on track to report data on late-stage studies evaluating Rinvoq in hidradenitis suppurativa and systemic lupus erythematosus indications next year. AbbVie believes that the next wave of potential approvals in Rinvoq could add roughly $2 billion to peak-year sales for the product.
ABBV’s Competition in the Immunology Space
The targeted market is highly competitive. A key player in this field is Johnson & Johnson (JNJ - Free Report) , which markets two blockbuster drugs, Stelara and Tremfya. Both of these J&J medications are approved for multiple immunology indications, including UC and CD. Since Stelara lost U.S. patent exclusivity earlier this year, J&J has shifted its focus to Tremfya to maintain its market position.
Another pharma giant expanding its presence in immunology is Eli Lilly (LLY - Free Report) , following the FDA approval of Omvoh for the UC indication in late 2023. Omvoh marked Lilly’s first immunology drug approved for a type of IBD in the United States, playing a key role in expanding its portfolio in this therapeutic area. The Lilly drug received FDA approval for the CD indication in January.
ABBV’s Price Performance, Valuation and Estimates
Shares of AbbVie have outperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a premium to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 16.19 times forward earnings, a tad higher than its industry’s average of 15.84. The stock is also trading above its five-year mean of 13.36.
Image Source: Zacks Investment Research
Bottom-line estimate movements for 2025 and 2026 have declined over the past 30 days.
Image Source: Zacks Investment Research
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.